Opinion

Video

Safety Outcomes with Leuprolide

Author(s):

Paul Sieber, MD

In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      2 experts in this video
      Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
      2 experts in this video
      The Current Landscape of ADT in Prostate Cancer
      Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
      Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Related Content
      Aquablation procedures for prostate cancer completed at ambulatory surgery center
      July 24th 2025

      Aquablation procedures for prostate cancer completed at ambulatory surgery center

      Hannah Clarke
      The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation
      Published: July 22nd 2025 | Updated: July 23rd 2025

      Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

      Hannah Clarke
      The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      July 18th 2025

      Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

      Hannah Clarke
      In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
      Urology in focus: Key moments from 2025
      July 18th 2025

      Urology in focus: Key moments from 2025

      Hannah Clarke
      Take a look back through some of the top stories from the first half of the year.
      © 2025 MJH Life Sciences

      All rights reserved.